JPWO2020106191A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106191A5 JPWO2020106191A5 JP2021528866A JP2021528866A JPWO2020106191A5 JP WO2020106191 A5 JPWO2020106191 A5 JP WO2020106191A5 JP 2021528866 A JP2021528866 A JP 2021528866A JP 2021528866 A JP2021528866 A JP 2021528866A JP WO2020106191 A5 JPWO2020106191 A5 JP WO2020106191A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- treatment
- steroid
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 150000003431 steroids Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- DYKZYSKWOHKZMF-UHFFFAOYSA-N 1-[2-(1H-imidazol-5-yl)ethyl]piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1CCC1=CN=CN1 DYKZYSKWOHKZMF-UHFFFAOYSA-N 0.000 claims 5
- 206010011224 Cough Diseases 0.000 claims 5
- 102000008070 Interferon-gamma Human genes 0.000 claims 5
- 108010074328 Interferon-gamma Proteins 0.000 claims 5
- 229960003130 interferon gamma Drugs 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 208000006673 Asthma Diseases 0.000 claims 3
- 230000001594 aberrant Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022184210A JP2023015333A (ja) | 2018-11-23 | 2022-11-17 | ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018141291A RU2712281C1 (ru) | 2018-11-23 | 2018-11-23 | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| RU2018141291 | 2018-11-23 | ||
| PCT/RU2019/050225 WO2020106191A1 (fr) | 2018-11-23 | 2019-11-22 | Production de glutarimide pour vaincre la résistance aux stéroïdes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184210A Division JP2023015333A (ja) | 2018-11-23 | 2022-11-17 | ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022508167A JP2022508167A (ja) | 2022-01-19 |
| JPWO2020106191A5 true JPWO2020106191A5 (fr) | 2023-01-25 |
Family
ID=69624712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528866A Pending JP2022508167A (ja) | 2018-11-23 | 2019-11-22 | ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 |
| JP2022184210A Pending JP2023015333A (ja) | 2018-11-23 | 2022-11-17 | ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184210A Pending JP2023015333A (ja) | 2018-11-23 | 2022-11-17 | ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220362230A1 (fr) |
| EP (2) | EP3884945A4 (fr) |
| JP (2) | JP2022508167A (fr) |
| KR (2) | KR20220162821A (fr) |
| CN (2) | CN114652721A (fr) |
| AU (2) | AU2019384626A1 (fr) |
| BR (1) | BR112021009801A2 (fr) |
| CA (1) | CA3120882A1 (fr) |
| CL (2) | CL2021001316A1 (fr) |
| EA (1) | EA201992646A1 (fr) |
| GE (1) | GEP20237467B (fr) |
| IL (2) | IL297533A (fr) |
| MD (2) | MD4851C1 (fr) |
| MX (2) | MX2021006032A (fr) |
| PH (1) | PH12021551152A1 (fr) |
| RU (1) | RU2712281C1 (fr) |
| WO (1) | WO2020106191A1 (fr) |
| ZA (2) | ZA202104247B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023177329A1 (fr) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Utilisation de 1-(2-(1н-imidazol-4-yl)éthyl)pipéridine-2,6-dione pour le traitement de la toux induite par des infections virales |
| WO2023191666A1 (fr) * | 2022-03-29 | 2023-10-05 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Forme cristalline de 1-(2-(1н-imidazol-4-yl)éthyl)pipéridine-2,6-dione, et utilisation de celle-ci |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9111874U1 (fr) * | 1991-09-23 | 1991-11-21 | Haag, Richard, 7181 Satteldorf, De | |
| KR100282575B1 (ko) * | 1992-02-07 | 2001-02-15 | 알버트엠.클릭만 | 염증성 피부병치료용 약제학적 조성물 |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| RU2404792C1 (ru) * | 2009-05-20 | 2010-11-27 | Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" | Средство для преодоления стероидной резистентности |
| BR112013020498A2 (pt) * | 2011-02-10 | 2016-08-09 | Genqual Corp | método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito |
| US9815814B2 (en) * | 2013-04-12 | 2017-11-14 | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
| RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
-
2018
- 2018-11-23 RU RU2018141291A patent/RU2712281C1/ru active
-
2019
- 2019-11-22 GE GEAP201915712A patent/GEP20237467B/en unknown
- 2019-11-22 EP EP19886166.8A patent/EP3884945A4/fr active Pending
- 2019-11-22 CA CA3120882A patent/CA3120882A1/fr active Pending
- 2019-11-22 MD MDA20210032A patent/MD4851C1/ro active IP Right Grant
- 2019-11-22 MX MX2021006032A patent/MX2021006032A/es unknown
- 2019-11-22 CN CN202210260820.9A patent/CN114652721A/zh active Pending
- 2019-11-22 BR BR112021009801A patent/BR112021009801A2/pt unknown
- 2019-11-22 IL IL297533A patent/IL297533A/en unknown
- 2019-11-22 CN CN201980076564.4A patent/CN113164464A/zh active Pending
- 2019-11-22 EA EA201992646A patent/EA201992646A1/ru unknown
- 2019-11-22 US US17/296,539 patent/US20220362230A1/en active Pending
- 2019-11-22 MD MDA20210050A patent/MD4844C1/ro active IP Right Grant
- 2019-11-22 EP EP22210617.1A patent/EP4218758A3/fr active Pending
- 2019-11-22 KR KR1020227040632A patent/KR20220162821A/ko active Application Filing
- 2019-11-22 WO PCT/RU2019/050225 patent/WO2020106191A1/fr active Application Filing
- 2019-11-22 JP JP2021528866A patent/JP2022508167A/ja active Pending
- 2019-11-22 KR KR1020217019084A patent/KR20210095652A/ko unknown
- 2019-11-22 AU AU2019384626A patent/AU2019384626A1/en active Pending
-
2021
- 2021-05-19 CL CL2021001316A patent/CL2021001316A1/es unknown
- 2021-05-20 IL IL283317A patent/IL283317A/en unknown
- 2021-05-20 PH PH12021551152A patent/PH12021551152A1/en unknown
- 2021-05-21 MX MX2022013503A patent/MX2022013503A/es unknown
- 2021-06-21 ZA ZA2021/04247A patent/ZA202104247B/en unknown
-
2022
- 2022-03-21 CL CL2022000683A patent/CL2022000683A1/es unknown
- 2022-09-21 ZA ZA2022/10444A patent/ZA202210444B/en unknown
- 2022-10-21 AU AU2022256212A patent/AU2022256212A1/en active Pending
- 2022-11-17 JP JP2022184210A patent/JP2023015333A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500862A5 (fr) | ||
| JP2006523216A5 (fr) | ||
| JP2021063088A5 (fr) | ||
| JP3987335B2 (ja) | シス−１−（２−（ヒドロキシメチル）−１，３−オキサチオラン−５−イル）−５−フルオロシトシンのｌ−鏡像体 | |
| JP2023002662A5 (fr) | ||
| JP2008501705A5 (fr) | ||
| JP2004526788A5 (fr) | ||
| JP2012502017A5 (fr) | ||
| JP2018518537A5 (fr) | ||
| JP2002532392A5 (fr) | ||
| JP2002508361A5 (fr) | ||
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| JP2007533687A5 (fr) | ||
| JP2005506370A5 (fr) | ||
| RU2005140652A (ru) | Кристаллическая форма агониста бетта2-адренергического рецептора | |
| JP2001518509A5 (fr) | ||
| JP2020520359A5 (fr) | ||
| SA07280161B1 (ar) | استخدام أجوميلاتين في الحصول على الأدوية المطلوبة لعلاج اضطراب القلق العام | |
| JP2005519893A5 (fr) | ||
| JP2006522023A5 (fr) | ||
| JP2019531286A5 (fr) | ||
| JP2005512946A5 (fr) | ||
| JP2019516756A5 (fr) | ||
| JP2007527409A5 (fr) | ||
| JPWO2020106191A5 (fr) |